$CLSH
CLS Holdings USA, Inc. Stock $clsh

$clsh Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000118518523000917 Filed on August 24, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$5.115M	$5.577M	$23.13M
YoY Change	-15.39%	-9.46%	2.08%
Cost Of Revenue	$2.841M	$4.837M	$13.33M
YoY Change	-5.4%	54.32%	19.83%
Gross Profit	$2.274M	$740.7K	$9.804M
YoY Change	-25.25%	-75.52%	-15.04%
Gross Profit Margin	44.46%	13.28%	42.38%
Selling, General & Admin	$2.730M	$1.539M	$11.11M
YoY Change	-14.75%	-48.3%	-10.55%
% of Gross Profit	120.05%	207.72%	113.29%
Research & Development	$1.465K		$809.00
YoY Change			-95.34%
% of Gross Profit	0.06%		0.01%
Depreciation & Amortization	$166.5K	$236.0K	$952.1K
YoY Change	-29.74%	8.08%	26.32%
% of Gross Profit	7.32%	31.87%	9.71%
Operating Expenses	$2.730M	$1.539M	$13.56M
YoY Change	-14.75%	-48.3%	9.24%
Operating Profit	-$456.0K	-$797.8K	-$3.760M
YoY Change	184.8%	-1698.9%	328.35%
Interest Expense	$457.5K	-$644.6K	$2.667M
YoY Change	-40.33%	-23.78%	24.06%
% of Operating Profit
Other Income/Expense, Net	$471.8K		-$8.863M
YoY Change	-172.25%		-1950.56%
Pretax Income	$15.79K	-$3.608M	-$12.62M
YoY Change	-101.94%	1218.99%	3064.58%
Income Tax	$477.5K	$668.7K	$2.221M
% Of Pretax Income	3024.03%
Net Earnings	-$463.8K	-$3.536M	-$13.80M
YoY Change	-59.61%	146.73%	488.93%
Net Earnings / Revenue	-9.07%	-63.4%	-59.65%
Basic Earnings Per Share	-$0.01		-$0.23
Diluted Earnings Per Share	-$0.01	-$0.05	-$0.23
COMMON SHARES
Basic Shares Outstanding	72.54M shares	72.52M shares	60.66M shares
Diluted Shares Outstanding	72.54M shares		60.66M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.035M	$998.4K	$998.4K
YoY Change	74.77%	-60.87%	-60.87%
Cash & Equivalents	$1.035M	$998.4K	$998.4K
Short-Term Investments
Other Short-Term Assets	$125.2K	$148.0K	$148.0K
YoY Change	-70.09%	-49.99%	-49.99%
Inventory	$3.051M	$3.013M	$3.013M
Prepaid Expenses	$125.1K	$149.0K
Receivables	$758.0K	$431.2K	$431.2K
Other Receivables	$0.00	$1.000K	$1.000K
Total Short-Term Assets	$4.969M	$4.592M	$4.592M
YoY Change	-16.71%	-33.3%	-33.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.775M	$2.913M	$4.555M
YoY Change	-34.28%	-32.92%	-29.9%
Goodwill	$557.9K	$557.9K
YoY Change	0.0%	0.0%
Intangibles	$201.3K	$209.1K
YoY Change	-82.67%	-82.43%
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$215.7K	$157.5K	$157.5K
YoY Change	-1.52%	-31.37%	-31.37%
Total Long-Term Assets	$5.302M	$5.479M	$5.479M
YoY Change	-43.09%	-38.74%	-38.74%
TOTAL ASSETS
Total Short-Term Assets	$4.969M	$4.592M	$4.592M
Total Long-Term Assets	$5.302M	$5.479M	$5.479M
Total Assets	$10.27M	$10.07M	$10.07M
YoY Change	-32.79%	-36.37%	-36.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.556M	$1.794M	$1.794M
YoY Change	52.94%	26.84%	26.84%
Accrued Expenses	$1.981M	$1.944M	$1.944M
YoY Change	42.44%	19.05%	19.05%
Deferred Revenue
YoY Change
Short-Term Debt	$78.54K	$471.4K	$471.4K
YoY Change	-93.19%	-53.47%	-53.47%
Long-Term Debt Due	$5.598M	$5.380M	$5.380M
YoY Change	-71.33%	-72.44%	-72.44%
Total Short-Term Liabilities	$17.44M	$16.34M	$16.34M
YoY Change	-39.41%	-41.87%	-41.87%
LONG-TERM LIABILITIES
Long-Term Debt	$5.664M	$5.986M	$5.986M
YoY Change	80.06%	101.51%	101.51%
Other Long-Term Liabilities	$1.426M	$1.544M	$1.544M
YoY Change	-21.99%	-18.46%	-18.46%
Total Long-Term Liabilities	$7.091M	$7.531M	$7.531M
YoY Change	42.55%	54.81%	54.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.44M	$16.34M	$16.34M
Total Long-Term Liabilities	$7.091M	$7.531M	$7.531M
Total Liabilities	$24.53M	$23.87M	$22.73M
YoY Change	-27.34%	-27.61%	-30.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$109.3M	-$108.9M
YoY Change	13.63%	14.51%
Common Stock	$7.255K	$7.255K
YoY Change	126.29%	-43.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$13.12M	-$12.66M	-$12.66M
YoY Change
Total Liabilities & Shareholders Equity	$10.27M	$10.07M	$10.07M
YoY Change	-32.79%	-36.37%	-36.37%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$463.8K	-$3.536M	-$13.80M
YoY Change	-59.61%	146.73%	488.93%
Depreciation, Depletion And Amortization	$166.5K	$236.0K	$952.1K
YoY Change	-29.74%	8.08%	26.32%
Cash From Operating Activities	$783.3K	$788.7K	-$229.9K
YoY Change	-153.58%	-231.38%	-92.72%
INVESTING ACTIVITIES
Capital Expenditures	$20.68K	$10.81K	$152.3K
YoY Change	-76.56%	-101.15%	-86.22%
Acquisitions
YoY Change
Other Investing Activities	-$58.18K	-$7.000K	$44.02K
YoY Change	-87.27%	-82.06%	-97.9%
Cash From Investing Activities	-$78.86K	-$17.81K	-$108.3K
YoY Change	-85.54%	-98.18%	-110.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$668.1K	-660.3K	-$1.215M
YoY Change	-1514.16%	-197.74%	-139.82%
NET CHANGE
Cash From Operating Activities	$783.3K	788.7K	-$229.9K
Cash From Investing Activities	-$78.86K	-17.81K	-$108.3K
Cash From Financing Activities	-$668.1K	-660.3K	-$1.215M
Net Change In Cash	$36.26K	110.6K	-$1.553M
YoY Change	-101.85%	-112.25%	-275.21%
FREE CASH FLOW
Cash From Operating Activities	$783.3K	$788.7K	-$229.9K
Capital Expenditures	$20.68K	$10.81K	$152.3K
Free Cash Flow	$762.6K	$777.9K	-$382.1K
YoY Change	-149.2%	129.74%	-91.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-05-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--05-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55546
CY2023	dei	Entity Registrant Name EntityRegistrantName	CLS HOLDINGS USA, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1352286
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1800 Industrial Road, Suite 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89102
CY2023	dei	Local Phone Number LocalPhoneNumber	888-260-7775
CY2023	dei	City Area Code CityAreaCode	888
CY2023	dei	Security12b Title Security12bTitle	N/A
CY2023	dei	Trading Symbol TradingSymbol	N/A
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	0	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72543141	shares
CY2023	dei	Auditor Firm AuditorFirmId	2738
CY2023	dei	Auditor Name AuditorName	M&K CPAS, PLLC
CY2023	dei	Auditor Location AuditorLocation	Houston, TX
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	998421	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2551859	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	431204	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	618227	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	3012932	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	3417602	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	148953	usd
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	295869	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	4591510	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	6883557	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2687146	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2073449	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913077	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4342434	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1641577	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2154517	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	588217	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	473308	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	209088	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1190285	usd
CY2023Q2	us-gaap	Goodwill Goodwill	557896	usd
CY2022Q2	us-gaap	Goodwill Goodwill	557896	usd
CY2023Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	0	usd
CY2022Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	469575	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157500	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	229500	usd
CY2023Q2	us-gaap	Assets Assets	10070648	usd
CY2022Q2	us-gaap	Assets Assets	15827764	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2728572	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2317898	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	634594	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	419206	usd
CY2023Q2	us-gaap	Loans Payable Current LoansPayableCurrent	471380	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	1013073	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	374004	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	309597	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	86887	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	71813	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	6752457	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4531782	usd
CY2023Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1439584	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3853051	usd
CY2022Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	19448821	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16340529	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	28112190	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1544283	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1893810	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200280	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	277180	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	902339	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	1681434	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	2033077	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	2693566	usd
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	3753051	usd
CY2022Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2023Q2	us-gaap	Liabilities Liabilities	23871220	usd
CY2022Q2	us-gaap	Liabilities Liabilities	32976746	usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72543141	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72543141	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32052021	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32052021	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	7255	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3206	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	96147784	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	77954748	usd
CY2023Q2	clsh	Stock Payable StockPayable	65702	usd
CY2022Q2	clsh	Stock Payable StockPayable	70092	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108879446	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95079817	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-12658705	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-17051771	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-1141867	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-97211	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13800572	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-17148982	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10070648	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15827764	usd
CY2023	us-gaap	Revenues Revenues	23133607	usd
CY2022	us-gaap	Revenues Revenues	22662895	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	13329600	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	12172650	usd
CY2023	us-gaap	Gross Profit GrossProfit	9804007	usd
CY2022	us-gaap	Gross Profit GrossProfit	10490245	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11107297	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11368100	usd
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1590742	usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	866288	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	13564327	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11368100	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3760320	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-877855	usd
CY2023	us-gaap	Interest Expense InterestExpense	2667004	usd
CY2022	us-gaap	Interest Expense InterestExpense	2149729	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6659359	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-178674	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-112139	usd
CY2023	clsh	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	145106	usd
CY2022	clsh	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	0	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	146092	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	2384	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
CY2023	clsh	Gain On Settlement Of Note Receivable GainOnSettlementOfNoteReceivable	348165	usd
CY2022	clsh	Gain On Settlement Of Note Receivable GainOnSettlementOfNoteReceivable	2740820	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8863290	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	478952	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12623610	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-398903	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2220675	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2041487	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-14844285	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2440390	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1044656	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-97211	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13799629	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2343179	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60655460	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	32032244	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60655460	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	32032244	shares
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15096820	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	281000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8780	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	98448	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2440390	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-17148982	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	11532680	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	656	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6659359	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-14844285	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-13800572	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-14844285	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-2440390	usd
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-178674	usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-112139	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	801535	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	327509	usd
CY2023	clsh	Gain On Settlement Of Note Receivable GainOnSettlementOfNoteReceivable	348165	usd
CY2022	clsh	Gain On Settlement Of Note Receivable GainOnSettlementOfNoteReceivable	2740820	usd
CY2023	clsh	Fair Value Of Shares Vested By Officers FairValueOfSharesVestedByOfficers	656	usd
CY2022	clsh	Fair Value Of Shares Vested By Officers FairValueOfSharesVestedByOfficers	8780	usd
CY2023	us-gaap	Impairment Of Investments ImpairmentOfInvestments	1590742	usd
CY2022	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	866288	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-6659359	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	146092	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	clsh	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	145106	usd
CY2022	clsh	Gain On Settlement Of Accounts Payable GainOnSettlementOfAccountsPayable	0	usd
CY2023	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	2384	usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	0	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	952133	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	753740	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	43122	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	79847	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-143901	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-64361	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-185916	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	111056	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-404670	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2189550	usd
CY2023	us-gaap	Increase Decrease In Operating Assets IncreaseDecreaseInOperatingAssets	-353797	usd
CY2022	us-gaap	Increase Decrease In Operating Assets IncreaseDecreaseInOperatingAssets	-324904	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	650483	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	709273	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	534680	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	235425	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2220675	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2041487	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1407	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-40895	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-331865	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-292424	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-229859	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3157670	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	152275	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1104806	usd
CY2023	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	304145	usd
CY2022	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	581714	usd
CY2023	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	usd
CY2022	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	62045	usd
CY2023	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	348165	usd
CY2022	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	2740820	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-108255	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	992255	usd
CY2023	us-gaap	Proceeds From Loans ProceedsFromLoans	1717115	usd
CY2022	us-gaap	Proceeds From Loans ProceedsFromLoans	2322875	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	2356806	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	1393966	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2500000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	365991	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	500000	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	75633	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10907	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1215324	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3052011	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1553438	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	886596	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2551859	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1665263	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	998421	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2551859	usd
CY2023	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	1476945	usd
CY2022	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	1656774	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	usd
CY2023	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	11532680	usd
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	281000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	4390	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	46745	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	229412	usd
CY2023	clsh	Original Issue Discount On Notes Payable OriginalIssueDiscountOnNotesPayable	0	usd
CY2022	clsh	Original Issue Discount On Notes Payable OriginalIssueDiscountOnNotesPayable	1875000	usd
CY2023	us-gaap	Interest Paid InterestPaid	3283	usd
CY2022	us-gaap	Interest Paid InterestPaid	0	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	12400	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	400795	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	98448	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1</b> –<b> BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On November 12, 2014, CLS Labs acquired 10,000,000 shares, or 55.6%, of the outstanding shares of common stock of Adelt from its founder, Larry Adelt. On that date, Jeffrey Binder, the Chairman, President and Chief Executive Officer of CLS Labs, was appointed Chairman, President and Chief Executive Officer of the Company. On November 20, 2014, Adelt adopted amended and restated articles of incorporation, thereby changing its name to CLS Holdings USA, Inc. Effective December 10, 2014, the Company exchanged shares of the Company’s common stock which were issued to CLS Labs in exchange for the 10,000,000 shares that it owned by virtue of the above-referenced purchase from Larry Adelt.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On April 29, 2015, the Company, CLS Labs and CLS Merger Inc., a Nevada corporation and wholly owned subsidiary of CLS Holdings (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby CLS Merger Inc. merged with and into CLS Labs, with CLS Labs remaining as the surviving entity (the “Merger”). As a result of the Merger, the Company acquired the business of CLS Labs and abandoned its previous business.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has been issued a U.S. patent with respect to its proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. The Company has not commercialized its patented proprietary process or otherwise earned any revenues from it. The Company is currently exploring the sale of the patent since the product the patent produces is currently illegal in the state of Nevada.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On December 4, 2017, the Company and Alternative Solutions, entered into a Membership Interest Purchase Agreement (the “Acquisition Agreement”), as amended, for the Company to acquire the Oasis LLCs from Alternative Solutions. Pursuant to the Acquisition Agreement, the Company initially contemplated acquiring all of the membership interests in the Oasis LLCs from Alternative Solutions. Just prior to closing, the parties agreed that the Company would instead acquire all of the membership interests in Alternative Solutions, the parent of the Oasis LLCs, from its members, and the membership interests in the Oasis LLCs owned by members other than Alternative Solutions. The Company received final regulatory approval to own its interest in the Oasis LLCs through Alternative Solutions under the revised structure of the transaction on April 26, 2022.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On October 20, 2021, the Company entered into a management services agreement (the “Quinn River Joint Venture Agreement”) through its 50% owned subsidiary, Kealii Okamalu, LLC (“Kealii Okamalu”), with CSI Health MCD LLC (“CSI”) and a commission established by the authority of the Tribal Council of the Fort McDermitt Paiute and Shoshone Tribe (the “Tribe”). The purpose of the Quinn River Joint Venture Agreement is to establish a business (the “Quinn River Joint Venture”) to grow, cultivate, process and sell cannabis and related products. The Quinn River Joint Venture Agreement had a term of 10 years plus a 10-year renewal term from the date the first cannabis crop produced is harvested and sold. Pursuant to the Quinn River Joint Venture Agreement, Kealii Okamalu leased approximately 5-10 acres of the Tribe’s land located along the Quinn River at a cost of $3,500 per quarter and managed the design, finance and construction of a cannabis cultivation facility on such tribal lands (the “Cultivation Facility”). Kealii Okamalu also managed the ongoing operations of the Cultivation Facility and related business, including, but not limited to, cultivation of cannabis crops, personnel staffing, product packaging, testing, marketing and sales. Packaged products were branded as “Quinn River Farms.” The Company provided 10,000 square feet of warehouse space at its Las Vegas facility and had preferred vendor status including the right to purchase cannabis flower and the business’s cannabis trim at favorable prices. Kealii Okamalu was required to contribute $6 million towards the construction of the Cultivation Facility and the working capital for the Quinn River Joint Venture. This amount was to be repaid from a portion of the net income of the Quinn River Joint Venture otherwise payable to CSI and the Tribe at the rate of $750,000 per quarter for eight quarters. Kealii Okamalu was to receive one-third of the net profits of the Quinn River Joint Venture.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">During the year ended May 31, 2023, the Company evaluated the joint venture with Kealii Okamalu, in light of its partner’s failure to make its required capital contributions. Due to the breach by its partner and the decision, therefore, by the Tribal Council to terminate the Quinn River Joint Venture Agreement, the Company believes it is in its best interest to impair the assets of Kealii Okamalu. This resulted in an impairment charge of $1,590,742 which was charged to operations during the year ended May 31, 2023.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 4, 2018, the former Attorney General, Jeff Sessions, rescinded the memorandum issued by former Deputy Attorney General James Cole on August 29, 2013 (as amended on February 14, 2014, the “Cole Memo”), the Cole Banking Memorandum, and all other related Obama-era DOJ cannabis enforcement guidance. While the rescission did not change federal law, as the Cole Memo and other DOJ guidance documents were not themselves laws, the rescission removed the DOJ’s formal policy that state-regulated cannabis businesses in compliance with the Cole Memo guidelines should not be a prosecutorial priority. Notably, former Attorney General Sessions’ rescission of the Cole Memo has not affected the status of the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) memorandum issued by the Department of Treasury, which remains in effect. This memorandum outlines Bank Secrecy Act-compliant pathways for financial institutions to service state-sanctioned cannabis businesses, which echoed the enforcement priorities outlined in the Cole Memo. In addition to his rescission of the Cole Memo, Attorney General Sessions issued a one-page memorandum known as the “Sessions Memorandum”. The Sessions Memorandum explains the DOJ’s rationale for rescinding all past DOJ cannabis enforcement guidance, claiming that Obama-era enforcement policies are “unnecessary” due to existing general enforcement guidance adopted in the 1980s, in chapter 9.27.230 of the U.S. Attorneys’ Manual (“USAM”). The USAM enforcement priorities, like those of the Cole Memo, are based on the use of the federal government’s limited resources and include “law enforcement priorities set by the Attorney General,” the “seriousness” of the alleged crimes, the “deterrent effect of criminal prosecution,” and “the cumulative impact of particular crimes on the community.” Although the Sessions Memorandum emphasizes that cannabis is a federally illegal Schedule I controlled substance, it does not otherwise instruct U.S. Attorneys to consider the prosecution of cannabis-related offenses a DOJ priority, and in practice, most U.S. Attorneys have not changed their prosecutorial approach to date. However, due to the lack of specific direction in the Sessions Memorandum as to the priority federal prosecutors should ascribe to such cannabis activities, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">William Barr served as United States Attorney General from February 14, 2019 to December 23, 2020. The DOJ under Mr. Barr did not take a formal position on federal enforcement of laws relating to cannabis. On March 11, 2021, United States President Biden’s nominee, Merrick Garland was sworn in as the U.S. Attorney General. During his campaign, President Biden stated a policy goal to decriminalize possession of cannabis at the federal level, but he has not publicly supported the full legalization of cannabis. It is unclear what impact, if any, the new administration will have on U.S. federal government enforcement policy on cannabis. Nonetheless, there is no guarantee that the position of the Department of Justice will not change.</p>
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-108879446	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reclassification</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Certain reclassifications, not affecting previously reported net income or cash flows, have been made to the previously issued financial statements to conform to the current period presentation.</p>
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	998421	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2551859	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	43122	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	79847	usd
CY2023Q2	us-gaap	Goodwill Goodwill	557896	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1044656	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-97211	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentrations of Credit Risk</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.</p>
CY2023	us-gaap	Advertising Expense AdvertisingExpense	613410	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1453727	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	809	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17361	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1641577	usd
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4116221	usd
CY2023	us-gaap	Revenues Revenues	23133607	usd
CY2022	us-gaap	Revenues Revenues	22662895	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	82135826	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75306426	shares
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-112139	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1590742	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	431204	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	618227	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	43122	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	79847	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	399728	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	297563	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2613204	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3120039	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	3012932	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	3417602	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2197934	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1918287	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1918287	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	374004	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1544283	usd
CY2023Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	usd
CY2022Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	2016	usd
CY2023Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	147953	usd
CY2022Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	293853	usd
CY2023Q2	us-gaap	Other Receivables OtherReceivables	1000	usd
CY2022Q2	us-gaap	Other Receivables OtherReceivables	0	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	148953	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	295869	usd
CY2022Q3	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3434647	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2111699	usd
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	12500	shares
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2687146	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2073449	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913077	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4342434	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	152275	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1104806	usd
CY2023	us-gaap	Depreciation Depreciation	837224	usd
CY2022	us-gaap	Depreciation Depreciation	638835	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	756808	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	331875	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	515457	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	353797	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	324904	usd
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4159621	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	28511	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	14899	usd
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P9Y
CY2022Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	221469	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	205888	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4159621	usd
CY2023Q2	us-gaap	Property Subject To Or Available For Operating Lease Accumulated Depreciation PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation	2312156	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	205888	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1641577	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	528100	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	520281	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	451671	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	227053	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	232001	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	509752	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2468858	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	550571	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1918287	usd
CY2023Q2	clsh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	1663593	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	588217	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	866288	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	209088	usd
CY2022Q2	clsh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	1663593	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	473308	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1190285	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	114909	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	114905	usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	866288	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	31036	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	31036	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	31036	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	30972	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	27700	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	57308	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	209088	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	656	usd
CY2022Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	18846721	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.2
CY2023Q2	us-gaap	Goodwill Goodwill	557896	usd
CY2022Q2	us-gaap	Goodwill Goodwill	557896	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	157500	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	229500	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157500	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	229500	usd
CY2022Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.4
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3400652	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6801298	shares
CY2022Q3	clsh	Warrant Description WarrantDescription	each warrant issuable pursuant to the conversion of such debentures is exercisable for one share of the Company’s common stock at a price of $0.40 per share
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1793585	usd
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1414074	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	311505	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	323254	usd
CY2023Q2	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	623482	usd
CY2022Q2	us-gaap	Other Deferred Credits Current OtherDeferredCreditsCurrent	580570	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2728572	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2317898	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	51389	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	779096	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	277017	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	5292635	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4813467	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	375000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	375000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	375000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	750000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	11981102	usd
CY2022Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	12204928	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	287167	usd
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	348993	usd
CY2023Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	86887	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	71813	usd
CY2023Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	200280	usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	277180	usd
CY2023Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	287167	usd
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	348993	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	86887	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	101707	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	98573	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2023Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	287167	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	187500000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72543141	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32052021	shares
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-4
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	290070272	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	574	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	12051397	shares
CY2022Q3	clsh	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	6025700	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.4
CY2018Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.2
CY2021Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.2
CY2018Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2102100	shares
CY2021Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5629094	shares
CY2021Q1	clsh	Warrant Description WarrantDescription	each warrant issuable pursuant to conversion of the Canaccord Debentures is exercisable for one share of the Company’s common stock at a price equal to $1.60 per share until March 31, 2024.
CY2021Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6229672	usd
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	3.2
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.2
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	973387	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2595697	shares
CY2021Q2	clsh	Warrant Description WarrantDescription	each warrant issuable pursuant to conversion of such debentures is exercisable for one share of the Company’s common stock at a price equal to 137.5% of the conversion price (presently $1.65 per share) until July 14, 2024
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2500000	usd
CY2022Q1	clsh	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	757576	shares
CY2022Q1	clsh	Warrant Description WarrantDescription	Each warrant allows the holder to purchase one share of the Company’s common stock at an exercise price of $1.65 per share for three years after its date of issuance
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.65
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21181449	shares
CY2023	clsh	Warrants Outstanding Weighted Average Remaining Contractual Term WarrantsOutstandingWeightedAverageRemainingContractualTerm	P2Y3M7D
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding	0.46
CY2023	clsh	Class Of Warrant Or Rights Exercisable ClassOfWarrantOrRightsExercisable	21181449	shares
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable	0.46
CY2021Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	20	acre
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	10000	usd
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13499411	shares
CY2021Q2	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding	2.12
CY2022	clsh	Granted Number Of Shares GrantedNumberOfShares	874666	shares
CY2022	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.65
CY2022	clsh	Class Of Warrant Or Rights Exercised ClassOfWarrantOrRightsExercised	0	shares
CY2022	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised	0
CY2022	clsh	Class Of Warrant Or Rights Cancelled Expired ClassOfWarrantOrRightsCancelledExpired	-12644153	shares
CY2022	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Cancelled Expired ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsCancelledExpired	2.09
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1729924	shares
CY2022	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding	1.98
CY2023	clsh	Granted Number Of Shares GrantedNumberOfShares	20232775	shares
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted	0.4
CY2023	clsh	Class Of Warrant Or Rights Exercised ClassOfWarrantOrRightsExercised	0	shares
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised	0
CY2023	clsh	Class Of Warrant Or Rights Cancelled Expired ClassOfWarrantOrRightsCancelledExpired	-781250	shares
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Cancelled Expired ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsCancelledExpired	0.6
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21181449	shares
CY2023	clsh	Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding	0.46
CY2018Q1	clsh	Class Of Warrant Or Rights Granted ClassOfWarrantOrRightsGranted	51310	shares
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	12500	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	12500	shares
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	36000	usd
CY2023	us-gaap	Revenues Revenues	23133607	usd
CY2022	us-gaap	Revenues Revenues	22662895	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-12558964	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-12941530	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	10574643	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	9721365	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2220675	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2041487	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3347183	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2563035	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3347183	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2563035	usd
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	15938966	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001522222

Files In Submission

Name	View Source	Status
0001185185-23-000917-index-headers.html	Edgar Link	pending
0001185185-23-000917-index.html	Edgar Link	pending
0001185185-23-000917.txt	Edgar Link	pending
0001185185-23-000917-xbrl.zip	Edgar Link	pending
cls20230531_10k.htm	Edgar Link	pending
cls20230531_10kimg001.jpg	Edgar Link	pending
cls20230531_10kimg002.jpg	Edgar Link	pending
clsh-20230531.xsd	Edgar Link	pending
ex_559365.htm	Edgar Link	pending
ex_559366.htm	Edgar Link	pending
ex_559368.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
clsh-20230531_cal.xml	Edgar Link	unprocessable
clsh-20230531_def.xml	Edgar Link	unprocessable
clsh-20230531_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cls20230531_10k_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
clsh-20230531_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLSH
CLS Holdings USA, Inc. Stock $clsh

2023 Q3 Form 10-K Financial Statement

#000118518523000917 Filed on August 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSH CLS Holdings USA, Inc. Stock $clsh

2023 Q3 Form 10-K Financial Statement

#000118518523000917 Filed on August 24, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLSH
CLS Holdings USA, Inc. Stock $clsh